The Capsugel deal included 40% equity, compared with 27% on the Del Monte deal.

FORBES: KKR's Henry Kravis: 'Any Fool Can Buy A Company'

Capsugel manufactures a variety of capsules (hard gelatin, liquid-filled and vegetarian to name a few) used by pharmaceutical and nutrition companies.

FORBES: Pfizer's Capsugel To Go Private

However, Capsugel will still go into our database when the deal closes.

FORBES: Pfizer's Capsugel To Go Private

Who knows, a few years of solid revenue growth along with an acquisition or two and Capsugel could be big enough to make it.

FORBES: Pfizer's Capsugel To Go Private

Pharmaceutical giant Pfizer ( PFE) announced today that it is going to sell its Capsugel division to Kohlberg Kravis Roberts ( KKR), the private equity firm.

FORBES: Pfizer's Capsugel To Go Private

The same Capsugel deal today, Kravis said, would have a cost of capital near 9%, a reflection of the late-summer weakness in equity markets and window closing in the high-yield market, which moves on a hair trigger in turbulent times.

FORBES: KKR's Henry Kravis: 'Any Fool Can Buy A Company'